All Issue

2021 Vol.51, Issue 4 Preview Page

Original Article

31 December 2021. pp. 189-199
Abstract
References
1

World Health Organization. Polio vaccines: WHO position paper-March 2016. Wkly Epidemiol Rec 2016;91:145-68.

2

Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014;210(suppl. 1):S283-93. doi:10.1093/infdis/jiu295.

10.1093/infdis/jiu29525316847
3

World Health Organization. WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use. GAPIII. https://apps.who.int/iris/ handle/10665/208872.

4

Chumakov K, Ehrenfeld E. New Generation of Inactivated Poliovirus Vaccines for Universal Immunization After Eradication of Poliomyelitis. Clin Infect Dis 2008;47:1587-92.

10.1086/59331018990066PMC2596976
5

MFDS, 2020 Annual Report of National Lot Release). 11-1471057-000122-10, 2021. https://www.mfds.go.kr/brd/ m_231/view.do?seq=33049&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1.

6

World Health Organization. Recommendations for the preparation, characterization and establishment of international and other biological reference standards, Annex 2, WHO Technical Report Series, No 932. 2004. https://www.who.int/publications/m/item/annex2-trs932.

7

Martin J, Daas A, Milne C. European Pharmacopoeia biological reference preparation for poliomyelitis vaccine (inactivated): collaborative study for the establishment of batch No. 3. Pharmeur Bio Sci Notes 2016;2016:135-50.

8

MFDS, 2021National Standard Guidebook. 11-1471057-000380-10, 2021.7. http://www.nifds.go.kr/brd/m_522/list.do.

9

Crawt L, Atkinson E, Tedcastle A, Pegg E, Study participants (see Appendix 2), Minor P, et al. Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). WHO/BS/2018.2338.

10

Martin J, Dougall T, Stephens L, Cooper G, Minor PD, Heath A, et al. Report on the WHO collaborative study to establish the 3rd International Standard (replacement) for inactivated polio vaccine. WHO/BS/2013.2217.

11

Crawt L, Atkinson E, Tedcastle A, Elaine Pegg, the sIPV Study Group, Minor P, et al. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. J Infect Dis 2020;221:544-52.

10.1093/infdis/jiz07630788503
12

WHO Expert Committee on Biological Standardization. WHO manual for the preparation of secondary reference materials for in vitro diagnostic assays designed for infectious disease nucleic acid or antigen detection: calibration to WHO International Standards. Annex 6, WHO Technical Report Series, No. 1004, 2017. https://www.who.int/ bloodproducts/norms/SecStandManWHO_TRS_1004_web_Annex_6.pdf.

13

European Pharmacopoeia 10.0, General section, Vaccines, Poliomyelitis Vaccine(Inactivated), 01/2019:0214, Assay, D-antigen content. 2019. p.1025.

14

World Health Organization. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated), Annex3, WHO Technical Report Series, No.1024, https://www.who.int/publications/m/item/ poliomyelitis-vaccines-annex-3-trs-no-1024.

Information
  • Publisher :The Korean Society for Microbiology
  • Publisher(Ko) :대한미생물학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 51
  • No :4
  • Pages :189-199
  • Received Date :2021. 10. 06
  • Revised Date :2021. 12. 06
  • Accepted Date : 2021. 12. 07